

# NCI Budget Update

---

Douglas R. Lowy, M.D.  
Principal Deputy Director  
National Cancer Institute

Weston Ricks  
Director, Office of Budget and Finance  
National Cancer Institute

*October 23, 2024*

*Meeting of the Frederick National Laboratory Advisory Committee (FNLAC)*

# Thanks to...

- **Tenille McCatty, Linli Liu:** NCI Office of Extramural Finance & Information Analysis
- **Christine Burgess:** NCI Center for Research Strategy

# Making a Budget – It's Not All About Dough






# Things That Nibble Away



- Biomedical Research and Development Price Index (BRDPI)

# NCI's Research Buying Power is \$1.26B Less Than 2 Decades Ago

*Even with substantial increases in recent years*



# Things That Nibble Away




- Biomedical Research and Development Price Index (BRDPI)



- Competing Needs Across the Federal Government

# NCI Appropriations FY16 – FY24





# Things That Nibble Away



- Biomedical Research and Development Price Index (BRDPI)



- Competing Needs Across the Federal Government



- Emerging Opportunities

# Opportunities Over Time




- The Cancer Genome Atlas
- TARGET Initiative
- Center For Global Health
- RAS Initiative
- National Clinical Trials Network
- NCI Community Oncology Research Program
- Genomic Data Commons
- Cancer Moonshot
- Childhood Cancer Data Initiative

# NCI funds many critical components of cancer research through mechanisms outside the RPGs

- A PARTIAL list:
  - SPORE grants
  - Cancer Center support grants
  - Cancer training
  - Clinical trials networks
- We need to support these mechanisms in addition to the RPGs


# Increase in Unique NCI R01/R37 Applicants

Data include all MPI/PIs



Sources: IMPACII analysis of PIs of R01/R37 applications (type 1, 2, 9)

# Percentage of modular awards has decreased progressively from 63% in 2012 to 14% (~1 in every 7 awards) in FY 2023



Total no. of R01 awards made (unsolicited)

620

582

578

623

650

650

676

687


797

811

805


893

R01 award trends 2016-2023: Blue: Payline for experienced investigators;  
Green: total number of awards from unsolicited applications



2016-2023 from <https://gsspubssl.nci.nih.gov/blog/articles>

# Early-Stage Investigators (ESI): R01/R37 **payline**, **awards\*** 2016 – 2023



\*Unsolicited Applications  
2016-2023 from <https://gsspubssl.nci.nih.gov/blog/articles>

# Prioritization is even more important when the budget is constrained: some examples

- Developing new standards of care vs. research to increase uptake of current standards of care
- RPG pool: Investigator-initiated awards, early stage investigators, RFA's
- Cancer training
- Cancer Center support grants: Continue with Phase III? Continue to increase the number of designated centers?
- SPORE grants
- Clinical trials networks
- Cancer disparities: in under-represented groups, rural populations, and others
- Community engagement



# Prioritization: Some examples of hard choices made

- Prioritize development of new standards of care
- RPG pool: Protect new investigator-initiated awards, especially early stage investigators, reduce investment in RFAs; support non-competing awards at <100%
- Cancer training: Maintain the number of extramural trainees through specific trainee award mechanisms

# Thank you!

[www.cancer.gov](http://www.cancer.gov)

[www.cancer.gov/espanol](http://www.cancer.gov/espanol)

1-800-4-CANCER

[NCInfo@nih.gov](mailto:NCInfo@nih.gov)

[@NCIDirector](#)

[@TheNCI](#)



NATIONAL  
CANCER  
INSTITUTE